Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.

"Conflict of Interest JP has received personal fees from AbbVie, Arena, Boehringer Ingelheim, Celgene, Celltrion, Ferring, Galapagos, Genentech/Roche, GSK, Immunic, Janssen, Nestlé, Oppilan, Pfizer Inc, Progenity, Takeda, Theravance, and TiGenix. SV has received grant support from AbbVie, MSD, Pfizer Inc, and Takeda; speaker fees from AbbVie, Dr Falk Pharma, Ferring, Hospira, MSD, Takeda, and Tillotts; and consulting fees from AbbVie, Arena, Celgene, Eli Lilly, Ferring, Galapagos, Genentech/Roche, Gilead, Hospira, Janssen, MSD, Mundipharma, Pfizer Inc, Progenity, Second Genome, Shire, Takeda, and Theravance. MCD has received consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Gilead, Janssen, Pfizer Inc, Takeda, and UCB. EVL has received consulting fees from AbbVie, Allergan, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Calibr, Celgene, Celltrion, Eli Lilly, Gilead, Genentech, Iterative Scopes, Janssen, Ono Pharma, Pfizer Inc, Sun Pharma, Takeda, and UCB; and grant support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Gilead, Janssen, Pfizer Inc, Receptos, Robarts Clinical Trials, Takeda, Theravance, and UCB. NL, WW, LS, CS, IM, and XG are employees and stockholders of Pfizer Inc. J-FC has received grant support from AbbVie, Janssen, and Takeda; payment for lectures from AbbVie, Allergan, Amgen, Ferring, Shire, and Takeda; consulting fees from AbbVie, Amgen, Arena, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enterome, Ferring, Geneva, Genentech, Immunic, Ipsen, Janssen, Landos, MedImmune, Merck, Novartis, O Mass, Otsuka, Pfizer Inc, Shire, Takeda, TiGenix, and Viela Bio; and holds stock options in Genfit and Intestinal Biotech Development."

"Funding The clinical trials described in this article were sponsored by Pfizer Inc. Funding for medical writing support was provided by Pfizer Inc."

"All studies were registered with ClinicalTrials.gov [NCT01458574; NCT01470612] and were conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines, and were approved by the Institutional Review Boards and/or Independent Ethics Committees at each investigational centre participating in the studies or at a central Institutional Review Board. All patients provided written informed consent."